The newest ADHD agent: Its place in the therapeutic armamentarium

Advanced Studies in Medicine

Volumn 3, Issue 5 C, 2003, Pages

  Spencer, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANTICHOLINERGIC EFFECT; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GILLES DE LA TOURETTE SYNDROME; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; INSOMNIA; RATING SCALE; SEDATION; SIDE EFFECT; TIC; TREATMENT PLANNING; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 0038514985     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475-1488.
2. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776-784.
3. Spencer T, Heilgenstein J, Biederman J, et al. Results from two proof-of concept, placebo-controlled studies of atomoxetine in children with ADHD. J Clin Psychiatry. 2002;63:1140-1147.
4. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed. New York: Guilford Press; 1998.
5. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children with ADHD: a randomized, placebo-controlled dose-response study. Atomoxetine Study Group (2000). Pediatrics. 2001;108:e3.
6. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-120.
7. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol. 1985;25:296-301.
8. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
9. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67:149-156.
10. Spencer TJ, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
11. Popper CW. Alternatives to psychostimulant medications for treating ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
12. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
13. Newcorn J, Michelson D, Spencer T, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid ODD. Poster presented at: the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 25, 2002; San Francisco, Calif.
14. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficiy/hyperactivity disorder. Arch Gen Psychiatry. 2002;59:649-656.